BLAIV (INFUSION)POWDERPriority Review
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
EBANGA (ansuvimab) by Ridgeback Biotherapeutics is zaire ebolavirus glycoprotein-directed antibody interactions [moa]. Approved for zaire ebolavirus glycoprotein-directed antibody [epc]. First approved in 2020.
Drug data last refreshed 19h ago
Mechanism of Action
Zaire Ebolavirus Glycoprotein-directed Antibody Interactions
Pharmacologic Class:
Zaire Ebolavirus Glycoprotein-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
Ebola Virus Disease
Company
Worked on EBANGA at Ridgeback Biotherapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.